Recent developments and analyst perspectives have spotlighted Arbutus Biopharma (NASDAQ: ABUS), indicating a promising growth trajectory for this biopharmaceutical company. Chardan Capital's recent decision to raise its target price for Arbutus Biopharma from $4.00 to $4.50 signifies a potential
Rallybio, a small biotech firm, is on a mission to develop treatments for rare diseases, with a particular focus on fetal and neonatal alloimmune thrombocytopenia (FNAIT). This rare but potentially fatal disease results from platelet incompatibility between pregnant mothers and their unborn
The recent results of a clinical trial for an oral obesity drug developed by Viking Therapeutics have generated significant interest. The drug has shown promise in early-phase trials, capturing the attention of Wall Street analysts and investors alike. The study results, revealed at a medical
In the pharmaceutical industry, IT organizations face a critical decision when managing unified clinical development platforms: whether to adopt a product-centric BizDevOps model or a centralized Center of Excellence (CoE) model. This choice is pivotal as pharmaceutical companies strive to bring
Recent developments in the pharmaceutical industry underscore the volatile nature of advancements and market dynamics affecting prominent companies. The latest updates reveal a mix of struggles and achievements that highlight how pharmaceutical giants are navigating the complexities of drug
In a significant development, Monte Rosa Therapeutics, a biotechnology company based in Boston, has finalized a highly lucrative global exclusive development and commercialization license agreement with Novartis valued at up to $2.1 billion on October 28, 2024. Monte Rosa Therapeutics is focused on
